NERISONE OILY CREAM

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

DIFLUCORTOLONE VALERATE

Pieejams no:

GLAXOSMITHKLINE INC

ATĶ kods:

D07AC06

SNN (starptautisko nepatentēto nosaukumu):

DIFLUCORTOLONE

Deva:

0.1%

Zāļu forma:

CREAM

Kompozīcija:

DIFLUCORTOLONE VALERATE 0.1%

Ievadīšanas:

TOPICAL

Vienības iepakojumā:

3G/30G/60G

Receptes veids:

Prescription

Ārstniecības joma:

ANTI-INFLAMMATORY AGENTS

Produktu pārskats:

Active ingredient group (AIG) number: 0115864001; AHFS:

Autorizācija statuss:

CANCELLED POST MARKET

Autorizācija datums:

2016-09-30

Produkta apraksts

_ _
_Page 1 of 19_
PRODUCT MONOGRAPH
PR
NERISONE
®
(DIFLUCORTOLONE VALERATE)
Oily Cream 0.1% w/w
GSK Standard
Topical Corticosteroid
GlaxoSmithKline Inc.
7333 Mississauga Road
Mississauga, Ontario
L5N 6L4
Date of Revision:
January 26, 2017
Submission Control No: 200095
_©2017 GSK Inc., All Rights Reserved _
_NERISONE is a trademark of Bayer Schering Pharma Aktiengesellschaft,
used under license by GSK Inc. _
_ _
_ _
_Page 2 of 19_
TABLE OF CONTENTS
_ _
_ _
PAGE
PART I: HEALTH PROFESSIONAL
INFORMATION................................................... 3
SUMMARY PRODUCT INFORMATION
................................................................... 3
INDICATIONS AND CLINICAL USE
.........................................................................
3
CONTRAINDICATIONS
..............................................................................................
3
WARNINGS AND PRECAUTIONS
.............................................................................
4
ADVERSE REACTIONS
...............................................................................................
8
DRUG INTERACTIONS
...............................................................................................
8
DOSAGE AND ADMINISTRATION
...........................................................................
9
ACTION AND CLINICAL PHARMACOLOGY
....................................................... 10
STORAGE AND STABILITY
.....................................................................................
11
DOSAGE FORMS, COMPOSITION AND PACKAGING
........................................ 11
PART II: SCIENTIFIC INFORMATION
........................................................................
13
PHARMACEUTICAL INFORMATION
.....................................................................
13
REFERENCES
.............................................................................................................
16
PART III: CONSUMER INFORMATION
......................................................................
17
_ _